I've listened to the moonlight briefing when Jon made that comment. And I think he was more trying to justify not having interim efficacy data for an open-label study than to say that no one not even the people who are conducting the study would know the preliminary efficacy situation for each patient. The study design for efficacy mainly includes behavioral questionnaires and checklists. Parents probably would indicate to the researchers if the symptoms have improved qualitatively during each visit. They just would not collect quantitative data and run the statistics etc to see if they are statistically significant to avoid the parents/carers becoming biased after having that info.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)